Tuesday, May 12, 2015 10:44:58 AM
Dilutive financing - the bane of pretty much all pre-revenue, developmental stage biotech & tech stocks.
At least in this case - the terms for this EDA are not completely unreasonable. However - anytime that 35 MM freshly minted shares make their way into the market for a company with essentially nil in revenue and ongoing expenses,....
It makes it hard for the existing shareholders to realize any gain or feel they are making any headway - even when there is regular 'good news' coming out of the company.
IF (and this remains to be seen) by 'spending' 35 MM new shares HEB can finally get control of its own manufacturing destiny, and get a product completely through clinical testing,....
THEN there will be a longer-term payoff via revenue generation.
In the meantime - don't overextend on HEB - and IMO anybody who buys and holds here in the short & medium term with money that they can't do without is being dumb.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM